Companies: 10,795·Total market cap: $144.5T
Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.

CDTXNASDAQHealthcare
$221.38
+$0.00(+0.00%)
Market Cap$5.6B
P/E Ratio
52W High$221.42
52W Low$15.22
Overview

Cidara Therapeutics, Inc. (CDTX) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · CDTX · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-11.78cdtx eps ttm · cdtx earnings per shareEarnings history
PE Ratio (TTM)cdtx pe ratio ttm · cdtx price to earningsPE Ratio deep dive
Revenue (TTM)0.00cdtx revenue ttm · cdtx annual revenueFull revenue history
Dividend YieldNo Dividenddoes cdtx pay dividends · cdtx dividend yieldDividend history
Shares Outstanding6.3Mcdtx shares outstanding · cdtx floatShares outstanding history
Next EarningsTBAcdtx earnings date · cdtx next earningsEarnings history

Financial Snapshot

Full Financials
FY 2024Revenue$1.3M▼ 94.52% YoY
202220232024
cidara therapeutics, inc. revenue · cdtx revenue 2024
FY 2024Net Income-$169.8M▼ 640.60% YoY
202220232024
cidara therapeutics, inc. net income · cdtx profit 2024
FY 2024EPS$-26.75▼ 409.52% YoY
202220232024
cdtx eps · cidara therapeutics, inc. earnings per share 2024
TTM:Revenue: $0.00Net Income: -$184.7MEPS: $-11.78View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy11 analystsis cdtx a buy · cdtx analyst rating
Strong Buy
1
Buy
7
Hold
3
Sell
0
Strong Sell
0
12-Month Price Target
$150.00Low
$221.38Current
$177.88Avg Target19.65% downside
$221.50High
cdtx price target · cdtx 12 month forecast

Total: 11 · Buy rate: 72.7%

The CDTX analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $177.88, representing -19.65% downside from the current price of $221.38.

Stock Performance

Full History
1D+0.00%
1W+0.00%
1M+0.00%
3M+112.07%
YTD+0.16%
1Y+921.13%
5Y+334.08%

About Cidara Therapeutics, Inc.

CEOJeffrey L. Stein
IPO DateApr 15, 2015
Employees38
CountryUS
Websitecidara.com

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention an…

what is cidara therapeutics, inc. · cdtx stock overview · cidara therapeutics, inc. company profile · who is cidara therapeutics, inc. ceo · cdtx NASDAQ · cidara therapeutics, inc. headquarters · cidara therapeutics, inc. business segments

About Stock Overview & Key Data

Cidara Therapeutics, Inc. (CDTX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 15, 2015. As of the latest trading session, CDTX stock price is $221.38, with a market capitalization of $5.6B. The stock has returned +921.13% over the past 12 months and +0.16% year-to-date.

According to 11 Wall Street analysts, the consensus rating for Cidara Therapeutics, Inc. stock is Buy, with an average 12-month price target of $177.88. In fiscal year 2024, Cidara Therapeutics, Inc. reported revenue of $1.3M and net income of -$169.8M. For detailed data — including Cidara Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Cidara Therapeutics, Inc. (CDTX) stock price is $221.38. The stock is traded on NASDAQ under the ticker symbol CDTX. The 52-week range is $15.22 – $221.42.

CDTX stock priceCDTX quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice